Hi {{lead.First Name:default=edit me}},

Is dependability the primary factor you consider in a research partner? Did you know that Astellas has trusted Sanguine to prospectively procure biospecimens in 6 studies? Our partnership has covered diverse indications, including MS, Melanoma, and SCD. Clearly, we make a good team in implementing critical studies in humans.

Regardless of your pipeline stage (preclinical, translational, clinical) or disease indication you can customize the study size and scope to accelerate results with a prospective in-home collection or clinical site coordination, including:

  • Recallable patients with specific inclusion/exclusion criteria
  • Multiple specimens collected concurrently with a blood draw
  • Leukopaks from patients with confirmed conditions, such as autoimmune diseases
  • Preanalytical lab services (PBMC isolation, HLA typing, etc)

If you are contemplating a new study or would like to learn more for a future study, please respond directly to this email or schedule a time on my calendar.

Warm regards,

Alyssa Cook
Research Consultant
Sanguine Bio | Massachusetts

Schedule a Meeting
| www.sanguinebio.com